Department of Pathology, People's Hospital of Tongling City, Tongling, Anhui, China.
Department of Pathology, Heping Hospital Affiliated to Changzhi Medical College, Changzhi, Shanxi, China.
J Cancer Res Clin Oncol. 2024 Aug 27;150(8):400. doi: 10.1007/s00432-024-05874-4.
CD93 was recently identified as a promising therapeutic target for angiogenesis blockade in various tumors. Herein, we aimed to investigate the expression and clinicopathological significance of CD93 in gastric adenocarcinoma.
The gene expression of CD93 gastric adenocarcinoma was assessed using The Cancer Genome Atlas (TCGA) dataset. We then analyzed CD93 expression in 404 cases of gastric adenocarcinoma using immunohistochemistry. Clinicopathological associations and prognostic implications of CD93 expression were further investigated.
Using the TCGA dataset, we observed a significantly elevated CD93 gene expression in gastric adenocarcinoma compared to normal gastric tissues. The immunohistochemistry assay revealed a highly variable CD93 expression among patients with gastric adenocarcinoma, consistently demonstrating higher intratumor expression than in adjacent normal tissues. Notably, CD93 was predominantly expressed on the membrane of CD31 vascular endothelial cells. Furthermore, patients with higher CD93 expression demonstrated significantly poorer overall survival. Accordingly, higher CD93 expression was associated with deeper invasion and a higher possibility of lymph node metastasis and developing tumor thrombus. Cox proportional hazards regression suggested CD93 expression was an independent predictor for the prognosis of patients with gastric adenocarcinoma.
Our study revealed a significantly higher CD93 expression in gastric adenocarcinoma when compared with adjacent normal gastric tissues, and demonstrated its predominant expression on vascular endothelial cells. Our findings also highlighted the clinicopathological significance of CD93 in gastric adenocarcinoma, shedding light on a potential therapeutic target.
CD93 最近被确定为各种肿瘤血管生成阻断的有前途的治疗靶点。在此，我们旨在研究 CD93 在胃腺癌中的表达及其与临床病理的相关性。
使用癌症基因组图谱（TCGA）数据集评估 CD93 在胃腺癌中的基因表达。然后，我们使用免疫组织化学分析了 404 例胃腺癌中 CD93 的表达。进一步研究了 CD93 表达与临床病理特征和预后的关系。
使用 TCGA 数据集，我们观察到与正常胃组织相比，胃腺癌中 CD93 基因表达明显升高。免疫组织化学检测显示，胃腺癌患者的 CD93 表达存在高度变异性，肿瘤内表达始终高于相邻正常组织。值得注意的是，CD93 主要在 CD31 血管内皮细胞的膜上表达。此外，CD93 表达较高的患者总生存显著较差。因此，CD93 表达较高与浸润深度较深、淋巴结转移和形成肿瘤血栓的可能性更高相关。Cox 比例风险回归表明，CD93 表达是胃腺癌患者预后的独立预测因素。
与相邻正常胃组织相比，本研究发现胃腺癌中 CD93 表达明显升高，并证实其主要在血管内皮细胞上表达。我们的研究结果还强调了 CD93 在胃腺癌中的临床病理意义，提示其可能成为一个治疗靶点。
